Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based chemotherapy in the United States and China
Background and ObjectiveSmall-cell lung cancer (SCLC) is highly aggressive, and outcomes after relapse following platinum-based therapy remain poor. Tarlatamab, a DLL3-targeted bispecific T-cell engager, has demonstrated survival benefits in phase III trials. Given rising oncology expenditures, we e...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2026-04-01
|
| coleção: | Frontiers in Pharmacology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1719846/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|